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ABSTRACT
Objective: To assess the effectiveness of citalopram
for major depressive disorder (MDD) in adults, in
a systematic review of all published, randomised,
double-blind studies comparing it with a placebo.
Data sources: Cochrane Central Register of
Controlled Trials, Medline, PsychINFO and Embase.
Study selection: Randomised, double-blind,
placebo-controlled studies of citalopram in adults with
MDD were included. Studies with medically ill or
treatment resistant subjects were excluded, as were
studies of relapse prevention. Remission of MDD was
deﬁned as a primary outcome, and response or change
from baseline scores were deﬁned as secondary.
Data extraction: Remission, response and symptom
improvement scores on the Hamilton Depression
Scale, MontgomeryeAsberg Depression Rating Scale
and Clinical Global Impressions-Severity scales were
extracted. A random-effects meta-analysis was carried
out on the response rates and symptom improvement
scores. Included studies were examined for the
presence of bias and small study effects.
Results: Eight studies (n¼2025) met the inclusion
criteria. Two studies provided data on remission, but
only one of these showed a signiﬁcant difference
between citalopram and placebo (RR¼1.59, 95% CI
1.10 to 2.31). Meta-analysis of response rates in ﬁve
studies (n¼1010) revealed signiﬁcant superiority of
citalopram (RR¼1.42, 95% CI 1.17 to 1.73).
Meta-analysis of change from baseline scores in ﬁve
studies (n¼1541) gave a standardised mean difference
(Hedges’ g) of  0.27 (95% CI  0.38 to to  0.16),
showing a reduction in MDD symptoms to be
signiﬁcant for citalopram relative to placebo. There was
no evidence of any signiﬁcant small study effects. The
overall quality of reporting was poor, with insufﬁcient
information on the methodology or outcomes. Seven
studies received industry sponsorship.
Conclusions: Data concerning remission rates for
citalopram, relative to placebo, are inconclusive.
Response rates and symptom reduction scores in
citalopram-treated patients with MDD are signiﬁcantly
better relative to placebo treatment, according to
a meta-analysis of published reports. Evaluation of
unpublished data is necessary to assess more
deﬁnitively the effectiveness of citalopram for MDD.
INTRODUCTION
Citalopram is a selective serotonin-reuptake
inhibitor antidepressant, commonly used in
the treatment of major depressive disorder
(MDD). It is often recommended as a ﬁrst-
line treatment for this condition. This
recommendation, however, depends on the
quality of studies evaluating this drug, and
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ARTICLE SUMMARY
Article focus
- Systematic review and meta-analysis of
published randomised double-blind studies
comparing citalopram with placebo in adults
with major depressive disorder (MDD).
- Evaluation of the quality of published studies and
the risk of bias.
Key messages
- Data on remission rates for citalopram in MDD,
relative to placebo, are inconclusive
- Response rates and symptom improvement
scores are signiﬁcantly better in citalopram-
treated patients than in those taking placebo.
- The quality of reporting in published studies is
poor.
- Further evaluation of citalopram is necessary,
incorporating unpublished research.
Strengths and limitations of this study
- This review is based on a thorough search for
published placebo-controlled studies of citalo-
pram for adults with MDD, using a broad search
strategy. In a departure from previously
published reviews, this study assesses the risk
of bias and includes remission as a primary
outcome.
- This study would have been enhanced if the
missing data were available for a more complete
analysis, and unpublished studies satisfying
inclusion criteria were incorporated into this
review.
- This review was carried out by a single author.
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A re-examination of the role of citalopram in the
treatment of MDD is therefore necessary, taking into
account the quality of studies, risk of bias and different
measures of effectiveness. Remission of MDD is the most
clinically relevant measure of effectiveness that should
be sought when evaluating citalopram for MDD.
3e5 The
emphasis on remission when evaluating effectiveness can
be contrasted with earlier reviews of citalopram, focusing
on symptom improvement or response as the main
measure of outcome. Filling this gap in the literature,
I systematically reviewed all published randomised,
placebo-controlled studies of citalopram in adults with
MDD. I examined the quality of published studies and
the risk of bias, setting remission of MDD as the primary
measure of effectiveness in this review.
METHODS
Selection criteria
I selected published, randomised, double-blind studies
comparing citalopram with placebo among adult
participants over the age of 18, who were diagnosed as
having MDD using DSM-III,
6 DSM-IIIR,
7 DSM-IV
8 ICD-9
9
or ICD-10.
10 No upper age limit for study participants
was set. Studies with a third comparator (eg, another
antidepressant) were included, if a direct comparison
between citalopram and placebo treatments was
possible. Studies involving patients with severe medical
illness, other psychiatric disorder or substance abuse
were excluded from this review. Studies of MDD that
focused on relapse prevention, treatment augmentation
or treatment-resistant cases were also excluded, as these
studies would have introduced additional heterogeneity
into this evaluation.
Outcomes
Primary outcome
Remission of MDD. Remission was deﬁned as: a score
of <8 on the 17-item Hamilton Depression Scale
(HAM-D)
11; <9 on longer versions of HAM-D; <12 on the
MontgomeryeAsberg Depression Rating Scale
(MADRS);
12 or ‘not ill or borderline mentally ill’ on the
Clinical Global ImpressiondSeverity (CGI-S) scale.
13
These cut-off points provide a consistent deﬁnition of
‘remission.’
14 15
Secondary outcomes
Secondary outcomes were as follows: (a) response of
M D D .R e s p o n s ew a sd e ﬁ n e da sar e d u c t i o no fa tl e a s t
50% on the HAM-D or MADRS scales; or ‘much or very
much improved’ on the CGI-I (CGI-Improvement)
scale. HAM-D, MADRS and CGI-I have a similar sensi-
tivity to change in depression symptom ratings;
16 (b)
any reduction in the severity of depression, measured
as a reduction in scores relative to baseline values
(change from baseline), on the HAM-D, MADRS or
CGI scales.
Search methods
I carried out an electronic search of the Cochrane Central
Register of Controlled Trials, Medline (from 1950),
PsychINFO (from 1967) and EMBASE (from 1980) up to
February 2011. Articles with ‘citalopram,’ ‘placebo’ and
‘major or severe depression’ as keywords or exploded
MeSH terms, were searched by combining (exp citalo-
pram/OR citalopram.mp) AND (exp placebo/OR
placebo*.mp) AND (exp depressive disorder/OR
(depress* adj2 (major* or severe*)).mp). The term
‘placebos’ was used as a MeSH heading in the Medline,
Cochrane and EMBASE database searches, and ‘major
depression’ was used as a MeSH heading in the
PsychINFO search. No limits were set for these searches,
apart from the EMBASE search, which was limited to the
adult population because of the large number of ineli-
gible studies produced by the unrestricted search.
I examined the abstracts of all identiﬁed studies,
selecting randomised double-blind studies of citalopram
in patients with major depressive disorder. Reference lists
of review articles and other studies of citalopram were also
searched for publications satisfying the inclusion criteria.
I then obtained full text copies of these articles and
excluded those that: lacked a placebo control group;
involved children, adolescents, medically ill or treatment
resistant population; or were studies of relapse prevention
or of patients with another psychiatric illness.
Data collection
I extracted data into an electronic form with sections for
each study describing the methods used, study partici-
pants, interventions and measured outcomes, as well as
sections for bias evaluation. I reviewed each paper on at
least two occasions, to check for accuracy of selection
and data extraction, over a 3-month period.
Data on the characteristics of study participants were
entered into a table, recording the age and sex of
participants, sample sizes in the citalopram and placebo
treatment groups, medication doses, drop-out rates and
treatment duration. The number of subjects randomised
and the number included in outcome evaluation were
extracted from each study where possible. I recorded
baseline measures of symptom severity and the treat-
ment setting for each study.
I tabulated the proportions of patients who achieved
response or remission in the citalopram and placebo
arms of selected studies. I included the deﬁnitions of
‘response’ and ‘remission’ terms used and extracted the
change from baseline measures on the HAM-D, MADRS
or CGI depression scales.
Data analysis
Risk of bias was evaluated in accordance with the
Cochrane Handbook for Systematic Reviews of Interventions,
17
using the following parameters: adequacy of sequence
generation; allocation concealment; blinding of partici-
pants, personnel and outcome assessors; incomplete
outcome data; and selective outcome reporting. Small
study effects were investigated using a funnel plot. A
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late an overall RR of a response to citalopram, compared
with placebo, in a random-effects model, using Stata
V.9.2.
I carried out a meta-analysis of the change-from-
baseline scores on the 17, 21 and 24-item HAM-D scales
for participants included in outcome evaluation. I
applied a random effects model to calculate Hedges’ g
for standardised mean differences between citalopram
and placebo groups. Standard deviations (SD) were
computed from the p values, taken at the upper limit
and converted into a t-statistic. I used the formula
SD¼SE/O(1/Ne+1/Nc), where SE¼difference in means
of the two change from baseline scores divided by the
t-statistic, and Ne and Nc are the sample sizes in the
experimental and control groups respectively. I multi-
plied the result by  1 to convert a measure of symptom
reduction into an improvement score.
RESULTS
A search of the Cochrane Central Register of Controlled
Trials using the above search terms produced 31 unique
articles, Medline 244, PsychINFO 60 and EMBASE 202,
giving a total of 537 articles, after removing duplicates.
The selection process is described in ﬁgure 1.
I inspected the abstracts from the above searches and
selected 29 studies for possible inclusion. After exam-
ining full text copies of these studies, I compiled a ﬁnal
list of eight studies
18e25 that satisﬁed the inclusion and
exclusion criteria. Excluded studies lacked a placebo
control,
26e30 focused on relapse prevention
31 32 or were
studies of children,
33 34 medically ill
35e43 or treatment-
resistant subjects.
44 45 The study by Montgomery et al
46
was excluded, as the data in this study were reported in
a larger trial by Lepola et al.
22
Characteristics of included studies
The combined sample from eight studies consisted of
1237 subjects in the citalopram group and 788 in the
placebo group (total¼2025). The studies were brief, 2 to
8 weeks in duration, apart from one study,
25 which was
24 weeks in length. The mean age of participants was
42 years, with the age ranging between 18 and 74 years.
Females constituted two-thirds of the sample in most
studies, and the dose of citalopram ranged from 10 to
80 mg a day. One study
20 had only 16 participants. All
patients recruited in these studies were diagnosed as
having MDD using the criteria in the Diagnostic and
Statistical Manual of Mental Disorders III, III-R or IV.
Most participants were recruited in outpatient settings.
All studies, except for Gastpar 2006, received industry
sponsorship.
Risk of bias
The risk of bias in included studies is summarised in
table 1. Most studies provided insufﬁcient information to
determine whether the random sequence generation,
allocation concealment and blinding of outcome
assessors were adequate. Selective reporting of outcome
data was evident in all studies, as easily extractable
summary statistics such as remission and response rates
were often omitted from publication, or data were
presented in a form that could not be incorporated into
a meta-analysis. Most studies reported blinding of
participants and intention-to-treat analyses, using the
last-observation-carried-forward approach.
Baseline characteristics of subjects
Hamilton Depression Scale
Five studies provided mean baseline HAM-D
scores.
18 19 21 23 25 The patients in these studies had
mean baseline HAM-D scores above 17, showing that
they were moderately to severely depressed.
MontgomeryeAsberg Depression Rating Scale
Baseline mean MADRS scores were provided in four
studies.
18 19 22 25 The mean MADRS scores in these
studies were above 22, indicating that patients were
moderately (scores between 22 and 29) to severely
(scores of 30 or above) depressed.
Clinical Global Impressions-Severity
All studies, except for those of Frank et al
20 and
Montgomery et al
24 provided mean baseline CGI-S
scores. Average baseline scores in these study popula-
tions were above 4, indicating a moderate level of illness
severity. In the study by Gastpar et al,
21 more than 92% of
patients were assessed as moderately, markedly or
severely depressed.
Outcomes
Remission
Two of the eight studies reported remission rates. Stahl
25
reported a 45% remission rate in the citalopram
group, and 28% remission rate in the placebo group at
the end of a 24-week trial (RR¼1.59, 95% CI 1.10 to
2.31), with remission deﬁned as a score of <8 on HAMD-
17. Lepola et al
22 reported a remission rate of 42.8% in
the citalopram group, with remission deﬁned as a score
of <12 on MADRS, but this rate was not signiﬁcantly
different from placebo. This evaluation was based on Figure 1 Summary of the article selection process.
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placebo group were provided. No meta-analyses of this
small and incomplete dataset of only two studies were
carried out, given the risk of producing an unreliable
result.
Response rates
Five studies (n¼1010) reported response rates, and
these were included in the meta-analysis (ﬁgure 2).
Overall RR for symptom response with citalopram, rela-
tive to placebo, was 1.42 (95% CI 1.17 to 1.73), indi-
cating that the response of MDD in citalopram-treated
subjects was 42% more likely than in those taking
placebo. There was no signiﬁcant heterogeneity between
studies (I
2¼50.9%, p¼0.087). The study by Gastpar
et al
21 was considered suitable for inclusion in this meta-
analysis, despite it using a mixed deﬁnition of
responsed50% improvement or a ﬁnal score of <10 on
the HAM-D.
A funnel plot based on the ORs of response rates in
these ﬁve studies did not reveal any signiﬁcant small
study effects (ﬁgure 3).
Change from baseline
Five studies, with a total of 1541 subjects, were included
in the meta-analysis of change from baseline scores
(ﬁgure 4). The study by Lepola et al was excluded, as it
provided no information for calculating standard devia-
tions, and the studies by Frank et al and Montgomery et al
did not report the change from baseline measures for
their subjects.
Hedges’ g for the standardised mean difference in the
change from baseline scores, comparing citalopram with
the placebo group, was  0.27 (95% CI  0.38 to  0.16),
which converted to a small but signiﬁcant improvement
score of 0.27. This result indicates that the improvement
in the HAM-D scores of subjects treated with citalopram
was 0.27 standard deviations better than the improve-
ment in those treated with placebo. There was no
signiﬁcant heterogeneity in the change from baseline
HAM-D measures (I
2¼0%; p¼0.872) in the studies
included in the meta-analysis.
DISCUSSION
Summary of main results
Two studies provided data on remission rates for citalo-
pram relative to placebo: the difference in remission
rates was statistically signiﬁcant in one study, but not the
other. It is therefore not possible to draw deﬁnite
conclusions regarding this outcome on the basis of the
published data, and a further evaluation is required,
incorporating unpublished results.
Table 1 Risk of bias in included studies
Study
Random
sequence
generation
Allocation
concealment
Blind
participants
and personnel
Blind outcome
assessment
Incomplete
outcome data
Selective
reporting
Burke et al
18 Unclear Unclear Low Unclear Low High
Feighner and
Overo
19
Unclear Unclear Low Unclear Low High
Frank et al
20 Unclear Unclear Low Unclear Low High
Gastpar et al
21 Low Unclear Low Unclear Low High
Lepola et al
22 Unclear Unclear Low Unclear Low High
Mendels et al
23 Unclear Unclear Unclear Unclear Low High
Montgomery et al
24 Unclear Unclear Low Unclear High High
Stahl
25 Unclear Unclear Low Unclear Low High
Figure 2 Random effects meta-analysis of symptom
responses for citalopram and placebo.
Figure 3 Funnel plot of symptom response odds ratios for
citalopram and placebo.
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citalopram, relative to placebo, were statistically signiﬁ-
cant in these meta-analyses, each one based on a subset
of ﬁve studies. No signiﬁcant heterogeneity between
these studies was detected. These data provide support
for the use of citalopram in MDD, at least in the ﬁrst
8 weeks of treatment.
Small study effects were not evident in this review, as
there was no marked asymmetry on the visual inspec-
tion of the funnel plot. However, a formal test of
asymmetry was not performed, given the small sample
of ﬁve studies in this analysis. Publication bias is one
potential source of plot asymmetry, not evident here,
although this should be more fully assessed after
obtaining unpublished research.
The quality of reporting in the reviewed studies was
generally poor, with insufﬁcient data to reach conclu-
sions regarding the adequacy of randomisation, alloca-
tion concealment and blinding of assessors. Most studies
omitted data on the remission rates, and none of the
studies reported a full set of outcome variables in a way
that can be incorporated in a meta-analysis. Inadequate
reporting and industry sponsorship of these studies raise
the possibility of bias and carry a risk for the validity of
this review.
Agreements and disagreements with other studies or
reviews
My estimation of the standardised mean difference for
the change from baseline scores is similar to Hedges’ g of
0.31 calculated by Turner on the basis of published
studies.
47 Importantly, Turner revised the estimation of
citalopram’s effectiveness to 0.01 after including
unpublished results. My conclusions regarding the effect
of citalopram on the response and symptom improve-
ment in MDD are consistent with the earlier reviews of
this drug.
14 8 e50 Those reviews, however, have not
examined the risk of bias in published studies, or the
effect of citalopram on remission of MDD. Remission is
an important outcome in clinical practice,
45and my
study highlights the limited data on this outcome in
published research.
Limitations
This systematic review is limited to published studies. Its
results are subject to a review of unpublished research
and outcome data that are missing from published
reports. Nevertheless, this review may serve as a useful
summary of published data, highlighting the risk of bias
and the paucity of published research into the effect of
citalopram on remission of MDD.
This review has been undertaken by a single reviewer.
While a single reviewer may be able to select and extract
unambiguous data, additional reviewers can help reach
consensus regarding areas of ambiguity in published
reports. That consensus, however, should not replace
missing or ambiguous data, or substitute the importance
of adequate reporting that is necessary for a systematic
review.
CONCLUSION
The reviewed published studies show that citalopram has
a statistically signiﬁcant advantage over placebo with
respect to symptom improvement and response rates in
adults with MDD. Its role in symptom remission is less
clear, given the contradictory ﬁndings of the two studies
with remission data in this review. The quality of
reporting in the reviewed studies is poor, and further
evaluation of citalopram, incorporating unpublished
research, is necessary to evaluate more deﬁnitively its
effectiveness in MDD.
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